LIDDS AB (publ) (LIDDS.ST)
SEK 0.11
(-3.65%)
SEK 0.11
(-3.65%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -40.67 Million SEK | -11.08% |
| 2022 | -36.61 Million SEK | 1.75% |
| 2021 | -37.26 Million SEK | -15.29% |
| 2020 | -32.32 Million SEK | -35.69% |
| 2019 | -23.82 Million SEK | -513.95% |
| 2018 | -3.88 Million SEK | 41.81% |
| 2017 | -6.66 Million SEK | -0.51% |
| 2016 | -6.63 Million SEK | 15.47% |
| 2015 | -7.84 Million SEK | -11.87% |
| 2014 | -7.01 Million SEK | -76.03% |
| 2013 | -3.98 Million SEK | -4.18% |
| 2012 | -3.82 Million SEK | -4.76% |
| 2011 | -3.65 Million SEK | -90.31% |
| 2010 | -1.91 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -2.39 Million SEK | -164.49% |
| 2024 Q1 | -904 Thousand SEK | 77.26% |
| 2023 Q1 | -9.57 Million SEK | -7.87% |
| 2023 Q3 | -4.53 Million SEK | 38.63% |
| 2023 Q4 | -3.97 Million SEK | 12.27% |
| 2023 Q2 | -7.38 Million SEK | 22.86% |
| 2023 FY | -24.77 Million SEK | 32.34% |
| 2022 Q2 | -9.91 Million SEK | -1.62% |
| 2022 Q1 | -9.75 Million SEK | -9.36% |
| 2022 FY | -36.61 Million SEK | 1.75% |
| 2022 Q4 | -8.87 Million SEK | -9.79% |
| 2022 Q3 | -8.08 Million SEK | 18.45% |
| 2021 Q4 | -8.91 Million SEK | -14.29% |
| 2021 Q3 | -7.8 Million SEK | 20.06% |
| 2021 Q2 | -9.76 Million SEK | 9.51% |
| 2021 Q1 | -10.78 Million SEK | 13.77% |
| 2021 FY | -37.26 Million SEK | -15.29% |
| 2020 Q2 | -5.29 Million SEK | 33.54% |
| 2020 Q4 | -12.5 Million SEK | -90.67% |
| 2020 FY | -32.32 Million SEK | -35.69% |
| 2020 Q1 | -7.96 Million SEK | 47.36% |
| 2020 Q3 | -6.56 Million SEK | -23.92% |
| 2019 Q1 | -2.52 Million SEK | 49.13% |
| 2019 FY | -23.82 Million SEK | -513.95% |
| 2019 Q4 | -15.13 Million SEK | -441.38% |
| 2019 Q3 | -2.79 Million SEK | 17.11% |
| 2019 Q2 | -3.37 Million SEK | -33.54% |
| 2018 Q1 | -1.96 Million SEK | 10.61% |
| 2018 FY | -3.88 Million SEK | 41.81% |
| 2018 Q2 | -2.24 Million SEK | -14.26% |
| 2018 Q4 | -4.96 Million SEK | -193.81% |
| 2018 Q3 | 5.29 Million SEK | 335.78% |
| 2017 Q1 | -1.83 Million SEK | 13.34% |
| 2017 FY | -6.66 Million SEK | -0.51% |
| 2017 Q2 | -1.18 Million SEK | 35.45% |
| 2017 Q3 | -1.44 Million SEK | -21.74% |
| 2017 Q4 | -2.19 Million SEK | -52.05% |
| 2016 Q1 | -1.45 Million SEK | 10.57% |
| 2016 Q4 | -2.12 Million SEK | -32.14% |
| 2016 Q3 | -1.6 Million SEK | -10.84% |
| 2016 FY | -6.63 Million SEK | 15.47% |
| 2016 Q2 | -1.44 Million SEK | 0.55% |
| 2015 Q1 | -2.21 Million SEK | -20.99% |
| 2015 FY | -7.84 Million SEK | -11.87% |
| 2015 Q4 | -1.62 Million SEK | 10.28% |
| 2015 Q3 | -1.81 Million SEK | 17.0% |
| 2015 Q2 | -2.18 Million SEK | 1.22% |
| 2014 Q1 | -1.34 Million SEK | -21.31% |
| 2014 FY | -7.01 Million SEK | -76.03% |
| 2014 Q4 | -1.83 Million SEK | 2.98% |
| 2014 Q3 | -1.88 Million SEK | 3.58% |
| 2014 Q2 | -1.95 Million SEK | -46.04% |
| 2013 Q4 | -1.1 Million SEK | 16.63% |
| 2013 Q1 | -1.17 Million SEK | 0.0% |
| 2013 Q2 | -1.4 Million SEK | -19.42% |
| 2013 Q3 | -1.32 Million SEK | 5.89% |
| 2013 FY | -3.98 Million SEK | -4.18% |
| 2012 FY | -3.82 Million SEK | -4.76% |
| 2011 FY | -3.65 Million SEK | -90.31% |
| 2010 FY | -1.91 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | -248.98 Million SEK | 83.664% |
| Ziccum AB (publ) | -21.56 Million SEK | -88.655% |
| Modus Therapeutics Holding AB (publ) | -16.4 Million SEK | -147.997% |
| BioArctic AB (publ) | 252.64 Million SEK | 116.1% |
| Sprint Bioscience AB (publ) | -845 Thousand SEK | -4713.491% |
| Mendus AB (publ) | -100.65 Million SEK | 59.589% |
| Genovis AB (publ.) | 54.22 Million SEK | 175.011% |
| Intervacc AB (publ) | -93.57 Million SEK | 56.535% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -15.51 Million SEK | -162.21% |
| Active Biotech AB (publ) | -46.48 Million SEK | 12.499% |
| Magle Chemoswed Holding AB (publ) | 18 Million SEK | 325.854% |
| Bio-Works Technologies AB (publ) | -55.41 Million SEK | 26.604% |
| Aptahem AB (publ) | -10.1 Million SEK | -302.523% |
| Vicore Pharma Holding AB (publ) | -321.5 Million SEK | 87.349% |
| Kancera AB (publ) | -65.04 Million SEK | 37.465% |
| Infant Bacterial Therapeutics AB (publ) | -134.61 Million SEK | 69.785% |
| Fluicell AB (publ) | -26.87 Million SEK | -51.323% |
| Saniona AB (publ) | -81.06 Million SEK | 49.825% |
| Lipigon Pharmaceuticals AB (publ) | -12.37 Million SEK | -228.785% |
| Biovica International AB (publ) | -126.07 Million SEK | 67.738% |
| Spago Nanomedical AB (publ) | -42.5 Million SEK | 4.308% |
| AcouSort AB (publ) | -17.48 Million SEK | -132.596% |
| Xintela AB (publ) | -57.23 Million SEK | 28.939% |
| Abliva AB (publ) | -96.54 Million SEK | 57.872% |
| Egetis Therapeutics AB (publ) | -324.8 Million SEK | 87.477% |
| Karolinska Development AB (publ) | -3.5 Million SEK | -1060.456% |
| OncoZenge AB (publ) | -15.9 Million SEK | -155.779% |
| Amniotics AB (publ) | -29.07 Million SEK | -39.903% |
| 2cureX AB (publ) | -36.36 Million SEK | -11.855% |
| CombiGene AB (publ) | -36.3 Million SEK | -12.034% |
| Asarina Pharma AB (publ) | -14.64 Million SEK | -177.828% |
| Calliditas Therapeutics AB (publ) | -384.39 Million SEK | 89.419% |
| Camurus AB (publ) | 532.35 Million SEK | 107.64% |
| Corline Biomedical AB | -1.78 Million SEK | -2174.832% |
| IRLAB Therapeutics AB (publ) | -180.76 Million SEK | 77.499% |
| Isofol Medical AB (publ) | -41.68 Million SEK | 2.421% |
| I-Tech AB | 24.43 Million SEK | 266.458% |
| Hansa Biopharma AB (publ) | -788.49 Million SEK | 94.842% |
| Cyxone AB (publ) | -21.66 Million SEK | -87.775% |
| ExpreS2ion Biotech Holding AB (publ) | -105.96 Million SEK | 61.616% |
| Biosergen AB | -27.26 Million SEK | -49.18% |
| Cantargia AB (publ) | -290.01 Million SEK | 85.975% |
| NextCell Pharma AB | -43.17 Million SEK | 5.786% |
| Xspray Pharma AB (publ) | -180.76 Million SEK | 77.499% |
| Elicera Therapeutics AB (publ) | -17.09 Million SEK | -137.911% |
| Nanologica AB (publ) | -69.96 Million SEK | 41.864% |
| SynAct Pharma AB | -224.49 Million SEK | 81.882% |
| Annexin Pharmaceuticals AB (publ) | -44.17 Million SEK | 7.927% |
| Stayble Therapeutics AB (publ) | -23.95 Million SEK | -69.799% |
| Lipum AB (publ) | -37.25 Million SEK | -9.18% |
| BioInvent International AB (publ) | -369.94 Million SEK | 89.005% |
| Alzinova AB (publ) | -16.52 Million SEK | -146.181% |
| Oncopeptides AB (publ) | -253.44 Million SEK | 83.952% |
| Pila Pharma AB (publ) | -6.39 Million SEK | -536.202% |
| Guard Therapeutics International AB (publ) | -115.07 Million SEK | 64.654% |
| Scandinavian ChemoTech AB (publ) | -20.13 Million SEK | -101.966% |
| Simris Alg AB (publ) | -36.63 Million SEK | -11.025% |
| Diamyd Medical AB (publ) | -146.56 Million SEK | 72.249% |
| Xbrane Biopharma AB (publ) | -310.42 Million SEK | 86.897% |
| Ascelia Pharma AB (publ) | -110.91 Million SEK | 63.328% |
| Diagonal Bio AB (publ) | -11.56 Million SEK | -251.669% |